{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T20:38:15Z","timestamp":1776112695981,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Glioblastoma (GBM) is the most aggressive malignant brain tumor in adults. The first choice for GBM is surgery, and followed by a combination of radiotherapy and chemotherapy. There are limited treatments for patients with recurrent GBM. Relapsed patients usually have a worse prognosis, and with a median survival time of &lt;6 months. Anlotinib is a novel small molecule multi-target tyrosine kinase inhibitor that can inhibit tumor angiogenesis and inhibit tumor cell growth. This drug has been used to treat advanced lung cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We present a case of recurrent GBM was treated with anlotinib in this report. The patient was diagnosed with GBM in August 2016 and treated with surgery and temozolomide (TMZ) chemotherapy. She was diagnosed with recurrence in February 2017 following which she was treated with gamma knife and TMZ chemotherapy. In November 2017, the patient presented with decreased vision in left eye. She was given radiation and her left eye vision returned to normal after radiation. On May23, 2018, the patient reported a decrease in left visual acuity again.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Brain magnetic resonance imaging (MRI) showed progression of the disease, and the tumor invaded the left optic nerve.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>This patient was administer anlotinib 12\u200amg po qd (d1\u201314, 21days as a cycle). Three cycles anlotinib were given to this patient.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient reported her left visual acuity increased over 10 days after first cycle of anlotinib treatment. MRI scan revealed tumor volume shrinks, especially the part that invades the left optic nerve shrinks significantly at 26 days after anlotinib treatment on August 11, 2018. However, the tumor progressed in 2 months after using of anlotinib. From the beginning of the application of anlotinib to death, her survival time was 110 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Anlotinib treatment with mild side effects may be a new option for the patients with recurrent glioblastoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000015749","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T04:29:42Z","timestamp":1559190582000},"page":"e15749","source":"Crossref","is-referenced-by-count":17,"title":["Targeted therapy with anlotinib for patient with recurrent glioblastoma"],"prefix":"10.1097","volume":"98","author":[{"given":"Yajuan","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiandong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archneurol.2010.5","article-title":"Recent advances in therapy for glioblastoma","volume":"67","author":"Clarke","year":"2010","journal-title":"Arch Neurol"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11060-013-1339-4","article-title":"The role of targeted therapies in the management of progressive glioblastoma:a systematic review and evidence-based clinical practice guideline","volume":"118","author":"Olson","year":"2014","journal-title":"J Neurooncol"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/cas.13536","article-title":"Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor","volume":"109","author":"Xie","year":"2018","journal-title":"Cancer Sci"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"414","DOI":"10.6004\/jnccn.2011.0038","article-title":"A review of VEGF\/VEGFR-targeted therapeutics for recurrent glioblastoma","volume":"9","author":"Reardon","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.2147\/CMAR.S173323","article-title":"Bevacizumab combined with chemotherapy vs single-agent therapy in recurrentglioblastoma: evidence from randomized controlled trials","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"403","DOI":"10.6004\/jnccn.2011.0037","article-title":"Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis","volume":"9","author":"Wong","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/neuonc\/nov085","article-title":"A phase I study of cediranib incombination with cilengitide inpatients with recurrent glioblastoma","volume":"17","author":"Gerstner","year":"2015","journal-title":"Neuro Oncol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","article-title":"Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma","volume":"28","author":"Batchelor","year":"2010","journal-title":"J Clin Oncol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1158\/0008-5472.CAN-09-0814","article-title":"A \u201cvascular normalization index\u201d as potential mechanistic biomarker to predictsurvival after a single dose of cediranib in recurrent glioblastoma patients","volume":"69","author":"Sorensen","year":"2009","journal-title":"Cancer Res"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","volume":"31","author":"Tracy","year":"2013","journal-title":"J Clin Oncol"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1200\/JCO.2005.03.2185","article-title":"Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme","volume":"23","author":"Reardon","year":"2005","journal-title":"J Clin Oncol"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/2193-1801-3-111","article-title":"Response to imatinib as a function of target kinase expression in recurrentglioblastoma","volume":"3","author":"Hassler","year":"2014","journal-title":"Springerplus"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.31172","article-title":"Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma","volume":"124","author":"Reardon","year":"2018","journal-title":"Cancer"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11060-016-2092-2","article-title":"Randomized phase II study of axitinib versus physicians best alternative choiceof therapy in patients with recurrent glioblastoma","volume":"128","author":"Duerinck","year":"2016","journal-title":"J Neurooncol"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s11060-014-1680-2","article-title":"Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study","volume":"121","author":"Chheda","year":"2015","journal-title":"J Neurooncol"},{"key":"R19-20230914","first-page":"v8","article-title":"A randomized phase ii trial of vandetanib (zd6474) in combination with carboplatin versus carboplatin alone in adults with recurrent glioblastoma","volume":"16","author":"McNeill","year":"2014","journal-title":"Neurooncology"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/neuonc\/not161","article-title":"A single-arm phase II Austrian\/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)","volume":"16","author":"Hutterer","year":"2014","journal-title":"Neuro Oncol"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11060-012-0943-z","article-title":"A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma","volume":"110","author":"Pan","year":"2012","journal-title":"J Neurooncol"},{"key":"R22-20230914","first-page":"Se28","article-title":"Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature","author":"Grisanti","year":"2016","journal-title":"J Neurosurg Sci"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/neuonc\/noq025","article-title":"Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)","volume":"12","author":"Iwamoto","year":"2010","journal-title":"Neuro Oncol"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/jco.2008.26.15_suppl.2020","article-title":"Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601","volume":"26","author":"De Groot","year":"2008","journal-title":"J Clin Oncol"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nos264","article-title":"Phase I\/II study of sorafenib in combination with temsirolimus for recurrentglioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02","volume":"14","author":"Lee","year":"2012","journal-title":"Neuro Oncol"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/cncr.31219","article-title":"Phase 1\/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study\/Alliance N0572","volume":"124","author":"Schiff","year":"2018","journal-title":"Cancer"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2 PDGFR and FGFR1 Gene","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201905310-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T21:15:10Z","timestamp":1694726110000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201905310-00019"}},"subtitle":["A case report and literature review"],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":27,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000015749","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}